POMC and Bardet-Biedl syndrome: Phase III studies on this drug to treat rare causes of obesity, such as POMC deficiency, leptin receptor mutation, Prader-Willi syndrome, Bardet-Biedl Syndrome, and Alström syndrome, are currently under way [155].